Clinical Trials
30 trialsHER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
Centre Antoine Lacassagne
ISNA-Sein
Institut Bergonié
ADAPT
West German Study Group
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
Dana-Farber Cancer Institute
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy
Seoul National University Hospital
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Alliance for Clinical Trials in Oncology
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
University of California, San Francisco
Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer
Zhejiang Cancer Hospital
NEO-ZOTAC
Borstkanker Onderzoek Groep
NEOZOL
Hospices Civils de Lyon
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
University of California, San Francisco
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Virginia Commonwealth University
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
SCRI Development Innovations, LLC
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
Abramson Cancer Center at Penn Medicine
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase II Bevacizumab + Tax In Advanced Breast Cancer
Case Comprehensive Cancer Center
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
National Cancer Institute (NCI)
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Memorial Sloan Kettering Cancer Center
VSNBNAC
Gangnam Severance Hospital
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Mayo Clinic
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
University of California, Davis